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Glossary  
Analysis of covariance (ANCOVA) 
ANCOVA combines analysis of variance with regression. It is a linear model with a 
categorical and one or more additional continuous independent variables related to a 
dependent variable. The method uses the relation between the independent continuous 
variables and the dependent variable to reduce the error term variability and achieve 
more power for comparing effects of the categorical variable. 
 
Bonferroni-Holm 
Statistical method to correct α-error accumulation in multiple testing. 
 
Cytokeratin 
Generic name for a family of insoluble structure proteins. Cells in the epidermis contain 
a high amount of keratin. 
 
Cytokines 
Interleukins and interferones are groups of small signalling proteins termed cytokines. 
These proteins are released by cells in order to affect other cells. The immune system 
relies to a large part on cytokines. 
 
Dermis 
Layer of the human skin below the epidermis. Contains blood and lymph vessels. 
 
Epidermis 
Outermost layer of the skin 
 
Erythema 
Redness of the skin. 
 
Fluorescence microscopy 
Special form of optical microscopy based on fluorescence. The compound of interest is 
labelled with a fluorophore, a group that emits light after excitation at a somewhat 
different wavelength. This enables the detection of the emitted light only using a 
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suitable filter system. In biomedical applications antibodies are coupled to fluorophores 
in order to visualize the location of the target protein with in cells or protein interactions.  
 
Histology 
Microscopic study of cells and tissues. 
 
Immunohistology 
Microscopic study of tissue using antibodies that bind to tissue components and 
indicate their presence. 
 
Induration  
Dermal thickening causing the cutaneous surface to feel thicker and firmer. 
 
Mediator 
Molecule involved in intercellular communication to modulate a biological process. 
These processes also include malfunctions leading to a disease. 
 
Multi Epitope Ligand Cartography 
Mapping of several proteins in a single tissue sample using a sequence of fluorescence 
detection steps with different antibodies recognising specific proteins and their location. 
 
Pruritus 
Latin expression for itching. 
 
Scaling 
Loss of the outer epidermis layer in scale-like flakes (desquamation). 
 
Selectin 
Family of cell adhesion molecules involved in immune response. The expression of 
selectines may be stimulated by cytokines. 
 
T-cells 
T-cells belong to a group of white blood cells relevant for cell mediated immunity. 
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Topoproteome 
Derived from the greek expression topos meaning location and proteome, the entire set 
of proteins in a tissue, cell or cell compartment. Topoproteome refers to a protein 
pattern and the corresponding function performed within the tissue. 
 
 
List of abbreviations 
ANCOVA Analysis of Covariance 
APS  affected psoriatic skin 
BCA  Biostatistics Collaboration of Australia 
CRO  contract research organisation 
ET  epidermal thickness 
ICH  International Conference on Harmonization of Technical Requirements  
  for Registration of Pharmaceuticals 
GCP  Good Clinical Practice 
MELC  Multi Epitope Ligand Cartography 
N  number of patients 
PASI  Psoriasis Area Severity Index 
PEF  pixel event fraction 
PEN  pixel event normalized 
PGA  Physician’s Static Global Assessment 
SSQ  sum of squares 
UPS  unaffected psoriatic skin 
WPP  workplace project portfolio 
%BSA  percentage of affected body surface area 
 
Antibody libraries for psoriasis are explained in the supplementary material of reference 
[3]. In general, standard abbreviations were used for these markers to facilitate the 
search of additional biological information. 
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Preface 
 
1. Student’s role 
 
The project presented here is an exploratory analysis of sub-study data collected in a 
placebo-controlled, double-blind, randomized, multicenter clinical trial of psoriatic 
patients. As a member of the project team I participated in the planning and conduct of 
the complete study. The whole team acted in close collaboration with local, external 
German and international partners. The analysis of the main study was performed by 
an external contract research organisation (CRO), whereas the exploration of the sub-
study was my task. My contributions to the main study were 
 
 • Discussion of the trial design within project team 
 • Revision of electronic case record forms 
 • Revision of data management and statistical analysis plans 
 • Quality control of collected study data 
 • Checking of results presented by the CRO 
 • Interpretation of results from a statistical point of view 
 • Analysis and reporting of sub-study data 
 
 
2. Reflections on learning 
 
 Communication and planning 
In this project I learned that the planning of multicenter trials is a rather complex task as 
many processes are linked closely together and specialists from many different 
disciplines and – possibly different views - contribute to the work. Communications 
within the team were running smoothly and constructive. Planning was performed 
during regular or additional spontaneous meetings if necessary. Communication with 
external partners was performed by phone or email in general. However, this cannot 
replace face-to-face meetings to discuss controversial points and to create a faithful 
atmosphere. 
 
 Statistical principles, methods and computing 
A series of BCA courses was very helpful for me as I was involved the planning and 
analysis of the clinical trial from the beginning to the end. These included design of 
clinical trials (module DES), advanced clinical trials (ACT), clinical biostatistics (CLB), 
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linear models and regression (LMR) and analysis of longitudinal and correlated data 
(LCD). Further, I familiarized myself with statistical aspects of dermatology such as the 
grading of psoriasis severity. All computations were performed using the R-package. 
Thus, the project enabled me to become acquainted with statistical software beyond 
the programs used in the BCA courses. 
 
 
3. Teamwork 
 
 Communication with other team members 
Communication with other team members occurred directly, communication with sub-
study centres and the WPP supervisor also by email or phone.  
 
 Negotiation roles and responsibilities 
All before mentioned statistical analyses were performed by me, under consultation 
with the rest of the project team. 
 
 Working within timelines 
Working within timelines was not a major issue most of the time since I was integrated 
in the project team making the plans. This enabled me to plan my data analysis. For 
example, during the trial data were collected and checked continuously. Further, a 
series of scripts was programmed during the trial to facilitate data analysis. Even 
though there was a lot of preparation there was some time pressure after unblinding 
since all concerned persons were eager to get the results as soon as possible and 
there was overlap with other projects requiring statistical computing and consulting.  
 
 Helping others to understand statistical issues – teaching 
Communicating the idea behind statistical methods and the results in a way that can be 
understood easily by the biologists or clinicians was one of the challenging aspects of 
this project. 
 
 
4. Ethical considerations 
 
 Ethics and competent authorities 
The study fulfilled the requirements of the German drug law, the declaration of Helsinki 
and the Good Clinical Practice (GCP) guideline of the International Conference on 
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Harmonization of Technical Requirements for Registration of Pharmaceuticals(ICH).  It 
was approved by the ethics committee of the Federal State Berlin, local ethics 
committees and the Federal Institute for Drugs and Medical Devices. All patients 
received information about the nature, significance and implications of the study. They 
were informed about the right to refuse participation in the study at any time without 
giving reasons. All participants provided written informed consent.  
 
 Confidentiality issues 
The study was conducted under restrictions of the German Data Privacy Act. All data 
provided to me were made anonymous. 
 Some details of the protocol, study conduct and results were omitted from this 
portfolio for reasons of confidentiality and to protect proprietary information by the 
sponsor. The above restriction should not affect the understanding of the concepts and 
methods used. 
 The content of this document and the statements made therein represent the 
author's personal opinion and do not reflect any official position of Revotar 
Biopharmaceuticals AG or of any of its directors. 
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Project report 
 
1. Project report front sheet 
 
Project title Analysis of Biomarkers related to Psoriasis 
Location Revotar Biopharmaceuticals AG, Hennigsdorf, Germany 
Dates  2009 - main clinical trial and sub-studies   
  January to June 2010 - analysis of sub-study data 
 
 
 Context 
The clinical trial Safety and Efficacy Study of Bimosiamose Cream to Treat Psoriasis 
was conducted as a multicenter study at various sites located in Germany. The 
statistical analysis of main study with clinical endpoints was performed by an external 
CRO. In addition to the main study, two sub-studies were conducted at the Charité 
University Hospital Berlin and the University Hospital Magdeburg, Germany. The data 
sets obtained at these sites provide the opportunity to evaluate methods for analysis of 
biomarker data and to contribute to the planning of clinical studies involving skin 
biomarkers and to the development of novel topoproteomic techniques. 
 
 
 
 Student declaration 
I declare this project is evidence of my own work, with direction and assistance 
provided by my project supervisor Prof. R. Meister. This work has not been previously 
submitted for academic credit. 
 
 
 
 
Date          Michael Meyer 
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2. Abstract 
Introduction 
Psorias is a widespread inflammatory skin disease leading to scaly patches of the 
epidermis. The cause of psoriasis is not fully understood and the treatment is difficult 
due to the recurrent chronic nature. Many biomarkers have been proposed to 
characterize psoriasis. Nevertheless, there is clear lack of validated biomarkers that 
are involved in biochemical pathways of this disease, are associated with disease 
severity and are able to represent treatment effects.   
 
Objective 
The objective was to characterize biomarkers for monitoring of psoriasis severity and to 
study the association of clinical measurements, symptom scores and epidermal 
thickness of psoriatic plaques with biomarkers. 
 
Methods 
Skin biopsies of patients with mild to moderate psoriasis were studied in two different 
explorative substudies with 9 and 15 patients, respectively, to determine response of 
histologic, immunohistologic and topoproteomic markers in affected and unaffected 
psoriatic skin. Further, cytokines in blood samples were studied. Global ANCOVA was 
applied to analyse the association between biomarker response and severity 
measurements. Markers for treatment effect monitoring in small clinical trials were 
identified using the response difference between affected and unaffected psoriatic skin 
as a model system for treatment effects. 
 
Results 
The skin cell counts of CD4, CD8 and CD11c, the skin cytokines and psoriasis 
mediators IL-10, IL-20, IL-22, IFN-γ, IL-17A, IL-23A, S100A7 and the topoproteomic 
markers CD31, CD62L, CD62E and CD7 are significantly different in affected and 
unaffected psoriatic skin. The group of cytokines and psoriasis mediators is associated 
with the percentage of affected body surface area and epidermal thickness of affected 
11 
 
psoriatic skin. The group of topoproteomic markers is associated the epidermal 
thickness of and the local symptom score pruritus. In blood IL-8, IL-22 and CCL27 are 
significantly associated with the psoriasis area and severity index (PASI) and the 
percentage of affected body surface.  
 
Conclusion 
In summary, skin and blood samples of psoriatic patients have been studied in an 
explorative manner by means of biomarkers. The distribution of psoriasis related 
proteins and cells in dermis and epidermis was studied using the Global ANCOVA 
approach. It was shown that this method developed for microarray analysis is a 
versatile tool for biomarker studies in psoriasis. A series of promising biomarkers for 
psoriasis characterisation has been identified. These results may serve as a starting 
point for further marker validation and characterisation of biochemical mechanisms 
relevant for psoriasis. 
 
 
3. Introduction 
Psoriasis is a non-infective chronic skin disease with a prevalence of 2-3% in the 
western population.  Severe psoriasis can be treated by a systemic therapy, whereas 
a topical treatment appears to be more suitable for mild or moderate psoriasis. Over 
time therapy may lose efficacy and rebound effects may occur after stopping the 
treatment with current drugs. Thus, there is a need for suitable treatment alternatives. 
 The inflammatory disease leads to red scaly patches on the skin called psoriatic 
plaques [1, 2]. The disease is further characterized by a movement of immune cells 
into the epidermis where a series of biochemical processes is initiated, for example 
induction of inflammation and stimulation of skin cell (keratinocyte) proliferation. This 
leads to an increase of the epidermal thickness (Fig. 1). Psoriasis is also accompanied 
by an unusual expression of various proteins that may serve as markers for the 
disease. However, the role of these proteins, the suitability to characterize the psoriasis 
severity, the association with clinical symptoms is still up for discussion. Another 
decisive point is the question whether the unusual marker levels are the cause or the 
consequence of the disease. Answers to these questions may lead to the identification 
of novel drug targets for the treatment of psoriasis. Beyond all controversy there is 
clear need for validated markers.  
  From a more general perspective, biomarkers should be associated 
disease severity, capture treatment effects and their measurement should be 
convenient in order to be useful surrogate markers. 
markers indicating the correspondi
unaffected psoriatic skin are of considerable interest because they may reveal whether 
a marker level can be used to discriminate between different skin states and whether 
there is an association with clinical sy
progression and treatment effects. 
 
 
 
Fig. 1. Image of psoriatic skin with epidermis on top (black) and dermis below (gray). 
The latter compartment can be subdivided in vascular and extravascular regions.
Psoriasis is characterized by an increased epidermal thickness and extended rate 
ridges connecting epidermis and dermis.
 
In this respect 
ng protein expression level 
mptoms normally used to describe disease 
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The investigations described here address the before mentioned properties of 
biomarkers in psoriasis. Exploratory studies were conducted to characterize the 
performance of biomarkers in psoriasis monitoring, to support the development of new 
drugs and to evaluate suitable experimental and statistical tools. On the one hand, 
these studies comprised classical histological or immunohistological markers in skin or 
blood; on the other hand biopsies were analysed using Multi Epitope Ligand 
Cartography (MELC) [3-5]. Both methods provide a variety of data measured under a 
similar clinical setting and offer the possibility to evaluate the performance of statistical 
methods for quite different ratios of sample size and number of markers. In 
immunohistology the number of patents may exceed the number of biomarkers. In 
contrast, Multi-Epitope-Ligand-Cartography is able to provide a huge amount of 
topoproteomic data for a small number of patients. The latter method is a novel 
microscopic and robotic technique enabling the spatial analysis of a series of 
biomarkers in tissue. Currently, there is only limited knowledge of the performance of 
the method within a setting of a clinical trial. Therefore, the aim of this project is an 
explorative data analysis for a small set of patients since the experimental procedure 
and the image processing require a substantial effort. In particular, the following 
aspects are of importance for a further development of the method: 
 
 
 ▪ outline of a framework for data analysis 
 ▪ exploration of visualisation tools for complex data 
 ▪ selection of biomarkers related to psoriasis from a statistical point of view 
 ▪ analysis of the distribution of biomarker target proteins in different skin  
  compartments 
 ▪ exploration of the association between biomarker data and clinical scores 
 ▪ provision of  basic data to design further clinical studies 
 
 
4. Trial design 
Data were taken from of a multi-centre, double-blind, parallel clinical trial of mild to 
moderate psoriatic patients with a randomization ratio of 2:1 for the twice-daily 
treatment with a cream with or without test compound over 4 months [6]. Sample size 
calculations were performed to provide sufficient power for the primary clinical 
endpoint. For the explorative sub-studies discussed here no formal sample size 
calculations were performed. In contrast, the sub-studies were performed inter alia to 
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derive a basis for sample size calculations for future studies. In sub-study A 
immunohistologic markers and psoriasis relevant mediators were investigated in blood 
and skin biopsies, in sub-study B topoproteome analyses of skin biopsies were 
performed. In both sub-studies a representative target lesion was selected for each 
patient and punch biopsies of affected (APS) and unaffected (UPS) psoriatic skin were 
taken on baseline. Clinical assessments of psoriasis severity were performed on 
baseline as well. The local symptom scores refer to the target lesions used for the 
biopsies in order to study the relation between biomarker response and clinical 
symptoms. The analysis of these baseline data is described here. 
 
 
5. Data management 
Clinical assessments were taken directly from the electronic case record forms. These 
data were checked by clinical monitors. Immunohistological data were measured in 
triplicate and checked at the Charité University Hospital Berlin. Mean values were 
provided for statistical analysis as Excel sheets. Topoproteomic data were provided as 
comma separated files by the University Hospital Magdeburg and Revotar 
Biotechnology GmbH Magdeburg (Germany). The cleaning of sub-study data involved 
checking for missing or inconsistent values. Queries were resolved by direct contact 
with the clinical trial sites. 
 The Global Analysis of Variance (ANCOVA) method currently does not accept 
missing data; markers without any variation should be removed as well. Therefore, the 
immunohistological data were checked manually for non-varying markers or markers at 
the limit of quantification. For the topoproteomic data this simple approach is not 
feasible due to the large amount of data. Therefore the cleaning was performed using 
R-scripts detecting missing or non-varying data. Imputation techniques for missing data 
were not used. 
 
 
6. Biomarkers 
Sub-study Part A comprised analysis of histological or immunohistological markers in 
skin biopsies and blood. The aim was to analyse cellular and soluble, psoriasis relevant 
biomarkers. This includes immune cells in the skin (immunohistology), their degree of 
activation (cytokine/mediator mRNA) and blood biomarkers. 
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 More specifically, blood biomarkers (CCL27, IL-8, IL-17, IL-20, IL-22), skin cell 
counts  in dermis and epidermis (CD4, CD8, CD11c, CD68) and  a group of cytokines 
and psoriasis relevant mediators in the skin (IL-10, IL-20, IL-22, IFN-γ, CCL27, IL-17A, 
IL-23A, S100A7) were studied. The skin cell counts characterize the cellular infiltrate in 
a psoriatic plaque formed by T cells (CD4, CD8), dendritic cells (CD11c) and 
monocytes/macrophages (CD68). The blood biomarkers and skin biomarkers selected 
are cytokines of the interleukin family (IL-x), interferone-γ (IFN-γ), chemokine (C-C 
motif) 27 (CCL27) and protein S100-A7 known to be overexpressed in lesions of 
psoriatic patients. In general the biomarker data from sub-study A correspond to cell 
counts per square millimetre of epidermis or dermis, marker concentrations or relative 
expression compared to the standard hypoxanthine phosphoryl transferase 1. The 
blood biomarkers correspond to a global measure related to the whole body, whereas 
the skin cell counts, cytokines and mediators from biopsies may be considered as local 
quantities. A distinction of the skin compartments dermis and epidermis was made for 
skin cell counts, but not for expression data. Separate measurements for vessels were 
not attempted. 
 In sub-study B an antibody library representing 47 biomarkers was used to 
study skin samples by fluorescence microscopy (actin, c-myc , CCR4, CD11a, CD11c, 
CD13, CD138, CD15, CD163, CD1a, CD2, CD207, CD25, CD26, CD29, CD31, CD3, CD4, 
CD44, CD45, CD45RA, CD45RO,  CD49f, CD54,  CD56, CD62E, CD62L,  CD62P, CD68, 
CD7, CD8, CD90, CLA, collagen type IV, cytokeratin, cytokeratin10, cytokeratin14, 
Factor XIII subunit A , Foxp3, HLA-DQ, HLA-DR, Ki67, propidium iodide, RORγ/NR1F3, 
STAT3,  TIA1, vimentin). This selection of markers focuses on various entities 
presumably or actually related to psoriasis, for example selectins (CD62E, CD62L and 
CD62P), different types of T cells (CD4, CD8), Th17 cells (RORγ), regulatory T cells 
(Foxp3), natural Killer cells (CD56), markers for activation of different T-cells (CD45RA, 
CD45R0), monocytes/macrophages (CD68, CD163), neutrophil granulocytes (CD15), 
Langerhans cells (CD1a, CD207), dermal dendritic cells (CD163, Factor XIII), structural 
markers (vimentin, collagen type IV) and proteins relevant  for the adhesion and 
extravasation process (CD54). 
 Details of the antibody libraries are listed in the supplementary material of 
reference [3]. The topoproteome analysis enables separate measurements of the 
biomarkers in the epidermal, extravascular and vascular skin compartments. The 
dermis comprises the latter two compartments. For each compartment a summary 
measure depending on size and fluorescence intensity was calculated and used for 
statistical analysis as described below. 
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7. Clinical covariates 
The visual assessment enables a distinction between affected skin consisting of 
psoriatic plaques and unaffected psoriatic skin. The affected body surface area and the 
epidermal thickness are widely used clinical scores. Two global clinical assessment 
scores enable a more detailed view [7]. The Physician’s Static Global Assessment 
(PGA) of overall lesion severity ranges from 0 (cleared) to 5 (very severe). The 
Psoriasis Area and Severity Index (PASI) enables a quantitative assessment of typical 
signs of psoriatic lesions combined with the skin surface area involvement in order to 
evaluate the improvement of intensity of overall psoriasis severity and coverage: 
induration (thickness), erythema (redness), pruritus and scaling (desquamation).  
 The body is divided into the four sections head, upper extremities, trunk and 
legs to top of buttocks in order to calculate the PASI.  These sections are weighted by 
the corresponding fraction of the body surface 0.1, 0.2, 0.3 and 0.4, respectively.  For 
each body section erythema E, scaling S and induration I are scored separately from 0 
for absence of symptoms to 4 for maximum severity. Further, the percentage of 
affected skin in each section is graded from A = 0 for absence of symptoms to A = 6 for 
complete involvement.  Then the scores for symptom severity are added and weighted 
by size and grade for affected area.  
 score	   =  0.1 ∙  E	  +  S	 +  I	 ∙  A	 score   =  0.2 ∙  E  +  S +  I ∙  A score  =  0.3 ∙  E  +  S + I ∙  A score !    =  0.4 ∙  #E !  + S ! +  I !$ ∙  A ! 
 
Finally, the scores of all sections are summed up. PASI ranges from 0 for a healthy 
person to the maximum severity of 72. 
 PASI =  score	  + score + score    +  score !   
 
Target lesions used for biopsies were assessed using a local severity score comprising 
induration (0-5), erythema (0-5), scaling (0-5) and pruritus (0-3). The total severity 
score is the sum of the individual scores and ranges from 0 (clear) to 18 (very severe). 
The local severity scores and the PASI score are numbers without units. 
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8. Statistical Methods 
8.1 Representation of topoproteomic data 
Human skin consists of the epidermis and dermis, the hypodermis located below the 
dermis attaches the skin to the underlying bones and muscles. The dermis and 
hypodermis also contain vessels. The structure is rather irregular.  An image of a skin 
sample is shown in Fig. 1. This is a two-dimensional representation of the skin sample 
and the data analysis is based on such skin slices. It is possible to distinguish the 
individual compartments by fluorescence microscopy, but the irregular structure 
impedes a simple distinction of areas. For image analyses rectangular areas oriented 
approximately perpendicular to the skin surface were used. These surfaces have a 
standardized width. In contrast, the data are less clearly defined with respect to the 
depths of the skin sample. The punch biopsies with a depth of 7 mm are limited to the 
epidermis and dermis, but this is a rather crude value when viewed from a pixel 
perspective. Further, there is a varying epidermal thickness in each patient depending 
on the disease severity. Therefore, it is recommendable to use a data representation 
that is largely independent from the actual size of each skin compartment and 
determine the epidermal thickness separately.  
 The raw data termed PEN (pixel events normalized) refer to skin samples of 
normalized width. Basically, a binary vector is assigned to each pixel where each 
component of the binary vector corresponds to a specific biomarker. A quantitative 
evaluation of the fluorescence intensity is not yet implemented. Instead, each vector 
element is set to 1 when the fluorescence signal at a pixel exceeds a certain threshold, 
otherwise it is set to 0 [3]. The PEN values for each compartment correspond to sums 
over the individual pixel events. The fluorescence microscopic measurements enable a 
clear distinction of the epidermal, extravascular and vascular compartments of the skin. 
Thus, the PEN values are available for each compartment and each marker separately. 
However, the PEN values depend on the size of the compartments, which is not clearly 
defined. Therefore the pixel event fraction (PEF) was calculated from the raw data.  
 
&'( = ∑ '*+*,-.  
 
N number of pixels in the selected compartment (epidermal, extravascular or 
 vascular) 
Ei 1: fluorescence signal of selected marker exceeds threshold 
 0:  fluorescence signal of selected marker does not exceed threshold 
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This summary measure used for statistical analysis does not depend directly on the 
actual size of the compartment. Further, it may be interpreted as a measure for the 
concentration of the target protein in the selected compartment. An example for 
unaffected and affected psoriatic skin is presented in Fig. 2. The slope of the lines 
connecting the pixel event fraction of affected and unaffected psoriatic skin suggests a 
decrease in epidermis for each patient.  In contrast, there is a clear deviation in the 
slope of individual lines for the vascular and extravascular compartments. Often, 
changes in the latter compartments are less correlated, in particular when the number 
of pixels in the corresponding compartment is small or when the PEN is small. The 
former may happen for vessel since the proportion of this compartment may be rather 
small; the origin of the latter may be a low expression of the target protein in a given 
compartment. The vascular, extravascular and epidermal compartments can be 
distinguished in the heatmap Fig. 3, a false colour representation of the pixel event 
fraction. For example, the pixel event fractions of CD138 and the cytokeratin group of 
markers clustered at the bottom of the heatmap are high in the epidermis (bottom right 
corner), and low in the extravascular and vascular compartments. According to the 
map, there is no substantial difference between cytokeratin pixel event fractions of the 
latter compartments. Similarly, the markers clustered on the top, especially actin, 
CD31, CD54 and CD90,  show large expression in vessel (top left) and low expression 
in the other compartments. The before mentioned marker groups have rather constant 
pixel event fractions across the patients whereas others are highly variable. Further, it 
should be noted that vessel appears to be more variable than the other compartments. 
Finally, the difference between the columns referring to affected psoriatic skin and the 
neighbour columns referring to unaffected psoriatic skin within a given compartment is 
much more difficult to evaluate for many markers on the visual scale. The heatmap 
suggests that CD44 in vessel, CD1a and CD49f in the epidermis and CLA, CD2, CD3, 
CD62L, CD7, Factor XIII subunit A and Foxp3 in the extravascular compartment might 
be promising markers to distinguish affected from unaffected psoriatic skin. The small 
differences between affected and unaffected psoriatic skin are in line with the example 
Fig. 2. showing an overlap between the pixel event fractions of affected and unaffected 
psoriatic skin. 
 
 
 
19 
 
 
Fig. 2. Single measurement of pixel event fraction for CD8 in three compartments of 
affected and unaffected psoriatic skin. 
 
In conclusion, it is clearly possible to distinguish between skin compartments using 
selected markers as a probe. In contrast to the PEN value depending simultaneously 
on size and concentration of a marker, PEF is size independent. This is a clear 
advantage. When PEN is large in one sample compared to another one, it remains 
unclear whether this can be attributed to a larger size of the compartment, a higher 
concentration of a protein or both. Therefore, the interpretation is difficult. In contrast 
PEF reflects the concentration of a target protein. Using PEF, the determination of the 
skin compartment size can be performed separately. This is important for diseases 
such as psoriasis because the disease is associated with an increased epidermal 
thickness and this is an important clinical parameter to characterize the disease 
severity. Hence two different variables are available to characterize the disease. 
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Fig. 3. Heatmap depicting marker response according to disease status and skin 
compartment. Overall, pixel event fraction of 47 markers in three compartments is 
shown for affected and unaffected psoriatic skin.  Markers are sorted according to the 
dendrogram generated by hierarchical clustering with Euclidean distances and 
complete linkage agglomeration. Pixel event fractions in the range from 0 to 1 are 
colour coded according to a rainbow from red to magenta. 
 
In addition to the fluorescence microscopic measurements of individual biomarkers 
also termed single binders, pixel-wise coexpression measurements were performed. 
Four groups of coexpression PEN data were provided for each compartment. These 
were labelled in the following way: 
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00 both markers of pair A and B are not expressed simultaneously at the same 
 pixel 
10 marker A of the corresponding pair is expressed, marker B is not expressed 
01 marker B of the corresponding pair is expressed, marker A not expressed 
11 both markers of pair A and B are expressed simultaneously at the same pixel 
 
In principle, the study of N markers enables the measurement N × (N-1) /2 pairs per 
data set. Here the measurements were limited to 1029 of 1128 possible marker pairs 
AB in each set for N = 47. The coexpression sets 10 and 01 represent the expression 
of one marker and the lack of expression of the other one when measured at the same 
pixel. These data correspond to the upper and lower triangle of a matrix describing the 
pairwise expression. As there is no principal difference between both sets except for 
the sequence of the marker names, both sets were merged and presented as 
coexpression set 10 + 01. As an example, the coexpression profile of CD44 – CD29 is 
depicted in Fig. 4.The scatterplot matrix indicates that the expression profiles of the 
vascular and extravascular compartments are clearly different. The top cell in the 
extravascular compartment labelled 11 suggests that there is no simultaneous 
fluorescence for both markers in this compartment, neither in affected nor in unaffected 
psoriatic skin since the pixel event fraction is zero for both types of skin. Similarly, there 
is no expression of CD29 when CD44 is absent (01). The cells labelled 10 indicate 
some fluorescence caused by CD44 when CD29 is absent in the extravascular 
compartment. The column for the epidermis suggests that there is almost no 
simultaneous fluorescence of both markers (11). There is noticeable fluorescence of 
CD29 at pixels where CD44 is absent (10); whereas there is no florescence of CD44 
when CD29 is absent (01). The vessel column suggests that there is some 
fluorescence of CD29 in unaffected psoriatic skin when CD44 is absent (10). Similarly, 
there is some fluorescence of CD44 in affected psoriatic skin when CD29 is absent 
(01). 
 To sum up, it is possible to study in detail the simultaneous presence or 
absence of marker pairs. This might provide hints on biological functions provided that 
the targets of these markers are located at the same cell or when there is a well 
defined biological relation between these markers. The MELC technology may 
generate a tremendous amount of coexpression data for this purpose. However, it 
should be kept in mind that an increasing number of marker pairs may lead to an 
increasing number of false positive results and therefore a careful validation is 
necessary. 
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Fig. 4. Pixel event fraction showing the pairwise CD44 – CD29 coexpression in three 
compartments of affected and unaffected psoriatic skin for nine patients. Presence or 
absence of each marker of the pair is indicated by the cell labels 1 and 0, respectively. 
 
 
8.2 Global ANCOVA theory 
Among other approaches, linear models have been developed to analyse expression 
experiments under the influence of a given study design. Here, the Global ANCOVA 
method developed for gene expression analysis was used to explore histologic, 
immunohistologic and topoproteomic data in a unified manner. The method enables an 
analysis of marker groups where the members show coordinated changes under given 
conditions such as medical treatment or disease status. The approach is based on 
23 
 
linear models for each marker taking into account external conditions imposed by the 
study design [8, 9]. The method replaces multiple comparisons for many biomarkers by 
a global assessment for a whole group of biomarkers. This global approach does not 
suffer from problems of multiple testing. 
 In matrix terms, the linear model for each biomarker can be expressed by 
 /* = 01* + 2* 
 
where Y(i) is the response vector for biomarker i, β(i) is the marker-specific vector of 
regression coefficients, X is a matrix depending on the trial design and ε(i) is a vector of 
independent normal random variables with E [ε(i)] = 0 and  Cov [ε(i)] = σ(i)2. The design 
matrix X represents the independent variables. These variables consist of indicator 
variables for group membership like in analysis of variance and continuos variable 
variables for adjustment like in conventional ANCOVA. Finally, the individual models 
are assembled in a global linear model for p biomarkers. 
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In this global model all submatrices X corresponding to the different markers are 
identical as the response of all markers is related to the same set of covariates such as 
skin compartment.  The method enables the analysis of individual biomarkers as well 
as a global analysis. The aim of the Global ANCOVA is to prove the relevance of 
certain covariates in explaining the observed experimental data by comparing the full 
model containing all covariates and the reduced model lacking the covariate of interest. 
Similar to conventional ANOVA, sums of squares related to the covariates in the full 
and reduced models are calculated. Subsequently, the extra sum of squares principle 
is used to study the difference between the full and the reduced model [9]. Typical 
models used for analysis are listed below in Tab. 1 using R-language. 
 
 Global ANCOVA analysis estimates the significance of the variables specified in 
the model. It should be noted that complex models can be specified easily. However, 
this was avoided in order to keep the interpretation simple. The independent variables 
may be of numerical or categorical type. An example for the latter is the skin 
compartment adopting levels such as epidermis, extravascular compartment or vessel. 
The dependent variables are the measured marker responses or differences between 
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marker responses in affected and unaffected psoriatic skin. The intercept can be 
interpreted as a mean response for a set of markers or as a mean response difference 
between affected and unaffected psoriatic skin for a set of markers, respectively. 
Significance testing at the global level, however, is not yet implemented. Alternatively, 
reference cell coding can be used to refer to a specific compartment, but this scheme 
was not applied here. 
 
Tab. 1. Examples for models used for biomarker analyses of psoriatic skin biopsies. 
design factor full model reduced model explanation 
skin compartment ~compartment ~ 1 compartment = epidermis, 
extravascular or vessel 
compartment and 
clinical covariate 
~ compartment 
+ clinical 
~ compartment clinical = epidermal 
thickness, PASI or 
symptom score 
compartment by clinical 
covariate  interaction 
~ compartment 
* clinical 
~ compartment 
+ clinical 
interaction of compartment 
with clinical covariate (e.g. 
epidermal thickness) 
 
 
The Global ANCOVA package provides two different types for the decomposition of the 
sum of squares to study the effect of each factor in the linear model of biomarker 
expression. The sequential decomposition scheme adds the sum of squares of each 
model term after the other in a hierarchical manner. Therefore the sums of squares of 
all factors add up to the total sum of squares. Thus, each term is adjusted for the 
previous term, but not for the following terms. Sequential decomposition is meaningful 
when there is a natural logical or hierarchical order within the given factors. This type of 
decomposition is presently the only one that can be applied at the level of individual 
biomarkers, whereas at the global level additional type-III decomposition is 
implemented. This is the method of choice when there is no natural order of the factors. 
Each term is removed at a time from the full model. In other words each term is 
adjusted for all other terms in the model. The last term in both decomposition types is 
treated in an identical manner. The type-III decomposition was used when there is no 
well defined hierarchical order between the model terms. A typical example comprises 
the symptom scores having no obvious order for induration, scaling, pruritus and 
erythema. When there was only a single model term or a logical order, sequential 
decomposition was used. Further, sequential decompositions were used to study the 
change of individual marker responses between affected and unaffected psoriatic skin. 
Each intercept term resulting from sequential decompositions corresponds to the mean 
response difference between affected and unaffected psoriatic skin for the 
corresponding marker. The asymptotic p-value for the intercept term may then be used 
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to test whether the mean response change for each marker is significantly different 
from zero. 
 
8.3 Computational details 
All statistical calculations were carried out using R 2.10.10 [11]. In particular, the 
libraries Global ANCOVA 3.12.0 [12] and multtest 2.2.0 [13] of the Bioconductor project 
[14] were used. Prior to statistical analysis variance stabilizing transformations were 
applied to the data. Pixel event fractions were transformed by arcsin (√&'(), 
concentrations were log-transformed. At the global level permutation tests were used to 
estimate the significance of certain factors using the extra sum of squares principle. 
The corresponding p-values are labelled pperm. For sequential decompositions 
asymptotic p-values were used since the permutation approach is not yet implemented. 
Adjustments for multiple testing for sequential decompositions at the level of individual 
markers were performed using the Bonferroni-Holm method. The corresponding p-
values are labelled padj. A limit of α = 0.05 was used for significance tests. Additional 
details on the Bonferroni-Hom method and on significance testing are given in the 
appendix. 
 
 
9. Results 
In the sections below the main results are compiled. First, a short summary of the data 
is given. Subsequently, the analyses of blood markers, of markers in affected psoriatic 
skin and of the differences between affected and unaffected psoriatic skin in terms of 
markers are presented.  
 Apart from convenience, a useful biomarker should fulfil two conditions. On the 
one hand, it should be associated with disease severity to facilitate the use of 
biomarkers as prognostic factors. As mentioned above, global and local scores can be 
used to characterize the severity of psoriasis. Therefore the analysis of biomarker 
response in blood and affected psoriatic skin is accompanied by an analysis of the 
association between markers and clinical covariates. As there is no clear order 
between individual symptom scores, type-III decomposition has been used to study 
associations between markers and symptom scores throughout. Three different models 
were applied. The first focuses on the association between markers and global clinical 
scores such as PASI and percentage of affected body surface (%BSA), the second on 
local symptom scores and the third on epidermal thickness (ET).  
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 On the other hand, biomarkers should be able to capture treatment effects in 
clinical trials and therapy. A simple association between biomarker response and 
disease severity is not sufficient for this purpose. For blood biomarkers intervention 
trials are necessary to study biomarker response change after treatments.  Skin 
samples however, may serve as a model system study treatment effects under the 
assumption that a hypothetical treatment leads to a biomarker response change 
corresponding to the difference between affected to unaffected psoriatic skin. This 
enables a selection of biomarkers presumably useful for treatment effect monitoring. 
 
9.1 Data 
In general, there were only a few missing data in both sub-studies since the data 
analysed here were taken on baseline and drop-outs occurred at later time points. 
 Markers with a non-varying concentration close to zero in many samples were 
discarded since they are unsuitable to characterize changes in the severity status of 
psoriatic patients. Therefore the interleukins IL-17 and IL-20 in blood were excluded 
from further analyses. Similarly, the Physicians Global Assessment Score (PGA) was 
excluded from the analyses of an association between biomarkers and clinical scores 
as there was no PGA variation in all patients (Tab. 2). 
 
 
9.2 Patients 
For sub-study A fifteen patients were recruited, for sub-study B nine. All patients 
suffered from mild to moderate plaque psoriasis. The most relevant patient 
characteristics are summarized in Tab. 2.  
 
 
Tab. 2. Summary of demographic data and clinical scores. 
  
sub-study A sub-study B 
N 
 
2 f, 13 m 0 f,9 m 
age (years) mean (SD) 50 (13) 50 (12) 
PASI mean (SD) 8.9 (2.5) 10.3 (2.4) 
PGA median (range) 3 (3-3) 3 (3-3) 
induration median (range) 2 (1-3) 3 (3-5) 
erythema median (range) 3 (2-3) 3 (3-4) 
scaling median (range) 3 (2-3) 3 (3-5) 
pruritus median (range) 2 (0-3) 1 (1-3) 
total symptom score median (range) 10 (5-12) 11 (10-17) 
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Tab. 3. Global ANCOVA table for clinical covariates and three blood biomarkers. 
 
SSQ df MS F pperm 
clinical measurements      
PASI 3.59 3 1.20 7.50 0.003 
%BSA 1.77 3 0.59 3.69 0.033 
      
symptom measurements      
induration 0.39 3 0.13 0.53 0.620 
scaling 1.13 3 0.38 1.54 0.254 
pruritus 0.16 3 0.05 0.22 0.835 
erythema 0.44 3 0.15 0.60 0.484 
      
epidermal thickness      
ETAPS 0.86 3 0.29 1.29 0.292 
      
summary of dependent variables 
plasma concentration of IL-8, IL-22, CCL-27; N=15 
 
 
9. 3 Blood biomarkers 
Biomarkers may be grouped as global and local biomarkers. Blood biomarkers being 
distributed over the whole body belong to the former group, whereas all markers 
derived from biopsies are of the latter type.  
 Five different blood biomarkers were studied experimentally. The plasma 
concentrations of the interleukins IL-17 and IL-20, however, were below the limit of 
quantification and showed no clear variation in most patients. Thus, both interleukins 
appear to be of minor relevance for a characterization of mild to moderate psoriatic 
patients. Therefore they were excluded and only the markers IL-8, IL-22 and CCL 27 
were used for analysis with three different models (Tab. 3). There is a significant 
association between blood biomarkers and PASI (p = 0.003) when adjusted for the 
percentage of affected body surface area and a significant association of percentage of 
affected body surface area (p = 0.033) when adjusted for PASI. In contrast to the 
before mentioned global clinical scores, there is no evidence for association of the 
blood biomarker levels of IL-8, IL-22 and CCL 27 and local symptom scores, neither for 
the induration, scaling, pruritus and erythema  scores  nor for the epidermal thickness 
of affected psoriatic skin. 
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9.4 Affected psoriatic skin  
 Skin cell counts 
Four different skin cell counts determined in the dermal and the epidermal 
compartments of affected psoriatic skin were used for Global ANCOVA analysis to 
study the association with clinical scores using the before mentioned models (Tab. 4). 
In all models compartment is a significant factor when adjusted for the clinical 
variables. An example for the skin cell count in different compartments is shown in Fig. 
7. There is some complementarity to the blood biomarkers mentioned before. At the 
global clinical level there is no significant association with the PASI and percentage of 
affected body surface area, whereas the local symptom score scaling contributes 
significantly to the model. Further, the p-values for induration and erythema are quite 
low. Epidermal thickness of affected psoriatic skin does not contribute significantly to 
the reduction of the sum of squares.  
 
 Skin cytokines and psoriasis relevant mediators 
Eight different skin cytokines and mediators determined in affected psoriatic skin were 
used for Global ANCOVA analysis of an association with clinical scores using the same 
models as above (Tab. 5). At the global level there is evidence for an association 
between skin cytokine levels and percentage of affected body surface area, but not for 
PASI. Similarly, there is no evidence of association between skin cytokine level and 
local symptom scores. In contrast, there is a strong evidence for an association 
between epidermal thickness of affected psoriatic skin and cytokine expression. 
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Tab. 4.  Global ANCOVA table for skin cell counts in affected psoriatic skin with clinical 
covariates. 
 
SSQ df MS F pperm 
clinical measurements      
compartment 622.9 4 155.7 45.0 < 0.00001 
PASI 17.2 4 4.30 1.24 0.264 
%BSA 11.6 4 2.90 0.84 0.389 
      
symptom measurements      
compartment 622.9 4 155.7 59.8 < 0.00001 
induration 29.5 4 7.39 2.83 0.084 
scaling 58.7 4 14.7 5.63 0.019 
erythema 30.1 4 7.53 2.89 0.074 
pruritus 19.3 4 4.82 1.85 0.158 
      
epidermal thickness      
compartment 622.9 4 155.7 45.4 < 0.00001 
ETAPS 18.3 4 4.58 1.34 0.257 
      
summary of dependent variables 
CD8, CD8, CD11c, CD68 cell counts in dermis and epidermis; N = 15 
 
 
Tab. 5. Global ANCOVA table for skin cytokines and mediators in affected psoriatic 
skin with clinical covariates. 
 
SSQ df MS F pperm 
clinical measurements      
PASI 7.87 8 0.983 1.05 0.327 
%BSA 39.1 8 4.891 5.22 0.027 
      
symptom measurements      
induration 2.15 8 0.269 0.21 0.862 
scaling 1.50 8 0.188 0.15 0.946 
pruritus 13.1 8 1.632 1.28 0.273 
erythema 0.59 8 0.073 0.06 1.000 
      
epidermal thickness      
ETAPS 81.7 8 10.2 20.2 0.0003 
      
summary of dependent variables 
relative expression of IL-10. IL-20, IL-22, IFN-γ,IL-17A, IL-23A, CCL-27, S100A7; N = 15 
 
30 
 
 Topoproteomic single binder data  
For 47 markers pixel event fractions were determined in the extravascular, epidermal 
and vascular compartments of affected psoriatic skin. At the global level, compartment 
is a significant factor (Tab. 6). According to the sequential decomposition for each 
marker, 46 raw p-values for intercept (98%) and 40 raw p-values for the factor 
compartment (85%) are smaller than 0.05. After adjustment according to the 
Bonferroni-Holm procedure, 44 and 27 markers corresponding to 94% and 47%, 
respectively, remain below the limit of significance. Two diagnostic plots are presented 
below. The influence of each marker on the sum of squares can be seen in Fig. 5. The 
ratio between the bar heights and the reference line correspond to the nominator and 
denominator F-statistics for each marker which is a measure of the association 
between pixel event fraction and compartment. The graphical representation shows 
outstanding bar heights for actin, CD13, CD138, CD29, CD31,CD54, CD62E, CD62P, 
CD68, CD90, collagen type IV and all cytokeratines. The sample plot shown in Fig. 6 
visualizes the reduction of the sum of squares per sample. This suggests that almost 
all samples fit to the model since positive bars lead to a decrease of p-values, negative 
bars to an increase. 
 
Tab. 6. Global ANCOVA table for single binder pixel event fractions of 47 markers in 
three compartments with sequential decomposition for each marker. 
 
source of variation          SSQ df MS F praw 
compartment 51.1 94 0.543 93.84 0 
error 36.5 1128 0.006   
 
marker compartment 
 
praw padj 
actin 6.54·10-19 2.82·10-17 
c-myc 1.37·10-1 3.62·10-1 
CCR4 6.34·10-4 1.141·10-2 
CD11a 1.91·10-3 2.48·10-2 
CD11c 1.13·10-1 3.62·10-1 
CD13 2.63·10-9 8.60·10-8 
CD138 4.66·10-21 2.05·10-19 
CD15 3.54·10-2 2.12·10-1 
CD163 8.75·10-2 4.85·10-1 
CD1a 1.10·10-10 3.86·10-9 
CD2 3.29·10-4 6.91·10-3 
CD207 1.35·10-8 4.32·10-7 
31 
 
CD25 9.05·10-2 3.62·10-1 
CD26 6.19·10-8 1.92·10-6 
CD29 3.36·10-13 1.31·10-11 
CD31 6.35·10-16 2.67·10-14 
CD3 6.40·103 6.40·10-2 
CD62L 3.87·10-3 4.64·10-2 
CD4 1.12·10-4 3.19·10-5 
CD44 2.23·10-5 5.58·10-4 
CD45 3.07·10-6 8.24·10-5 
CD45RA 1.0410-3 1.67·10-2 
CD45RO 5.35·10-5 1.17·10-3 
CD49f 2.67·10-1 3.62·10-1 
CD54 7.33·10-14 2.93·10-12 
CD56 3.43·10-4 6.91·10-3 
CD62E 6.51·10-8 1.95·10-6 
CD62P 1.47·10-11 5.59·10-10 
CD68 3.05·10-6 8.24·10-5 
CD7 6.56·10-3 6.40·10-2 
CD8 1.56·10-2 1.25·10-1 
CD90 7.36·10-7 2.51·10-5 
CLA 1.35·10-3 1.95·10-2 
collagen type IV 1.50·10-14 6.14·10-13 
cytokeratin 2.48·10-21 1.12·10-19 
cytokeratin10 2.48·10-26 1.74·10-24 
cytokeratin14 7.10·10-28 3.33·10-24 
factorXIII subunitA 5.14·10-11 1.90·10-9 
Foxp3 3.75·10-2 2.12·10-1 
HLA-DQ 4.63·10-5 1.06·10-3 
HLA-DR 3.43·10-4 6.92·10-2 
Ki67 3.24·10-5 7.78·10-4 
propidium iodide 1.10·10-6 3.19·10-5 
RORγ/NR1F3 1.30·10-3 1.95·10-2 
STAT3 3.88·10-2 4.65·10-1 
TIA1 6.71·10-2 1.14·10-2 
vimentin 5.66·10-11 2.04·10-9 
all 0  
 
The extra sum of squares principle was used again to study the association of pixel 
event fractions with clinical covariates. The compartment term is significant for all 
models. This corresponds to the sequential decomposition shown in Tab. 6. There is 
no evidence for an association with the percentage of affected body surface, PASI or 
epidermal thickness.  The local symptom score pruritus appears to be significantly 
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associated with the pixel event fraction of affected skin. For induration, the significance 
limit is exceeded to a minor extent. 
 
 
Fig. 5. Marker plot for pixel event fraction of single binders. The bar height indicates 
the difference between the sum of squares of the full model with compartment term and 
reduced model without compartment. This indicates the influence of each single binder 
on the test statistic for the factor compartment. The reference line with residual mean 
square error is almost at zero. 
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Fig. 6. Sample plot for pixel event fraction of single binders. The bar height indicates 
the difference between the sum of squares of the full model with compartment term and 
to the reduced model without compartment. The sums of squares over all markers are 
represented for each sample.  
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Tab. 7.  Global ANCOVA table for clinical covariates and 47 single binders measured 
in affected psoriatic skin. 
 
SSQ df MS F pperm 
clinical measurements      
compartment 51.1 94 0.543 97.8 0 
PASI 0.375 47 0.0089 1.44 0.138 
%BSA 0.19 47 0.0041 0.73 1 
      
symptom measurements      
compartment 51.1 94 0.543 104.4 0 
induration 0.41 47 0.0087 1.68 0.091 
scaling 0.35 47 0.0074 1.42 0.143 
erythema 0.28 47 0.0060 1.16 0.283 
pruritus 0.68 47 0.0014 2.78 0.011 
error 2.45 940 0.0026   
      
epidermal thickness      
compartment 51.1 94 0.54 95.0 0 
ETAPS 0.35 141 0.0075 1.30 0.190 
      
summary of dependent variables 
PEF of 47 markers in 3 compartments (actin, c-myc , CCR4, CD11a, CD11c, CD13, CD138, 
CD15, CD163, CD1a, CD2, CD207, CD25, CD26, CD29, CD31, CD3, CD4, CD44, CD45, 
CD45RA, CD45RO,  CD49f , CD54,  CD56 , CD62E, CD62L, CD62P, CD68, CD7, CD8, CD90, 
CLA, collagen type IV, cytokeratin, cytokeratin 10, cytokeratin 14, FactorXIII subunit A , Foxp3, 
HLA-DQ, HLA-DR, Ki67, propidium iodide, RORγ/NR1F3, STAT3,  TIA1, vimentin);  N = 9 
 
 
According to the heatmap shown in Fig. 3, the pixel event fraction of cytokeratines is 
clearly different in the epidermis on the one hand and the extravascular and vascular 
compartments on the other hand. Therefore the distribution of cytokeratines in skin was 
investigated in more detail. For this purpose Global ANCOVA enables the specification 
of marker subgroups for analysis. For cytokeratin, cytokeratin 10 and cytokeratin 14 
rather low p-values can be achieved in the global model shown in Tab 8. The pairwise 
comparisons by compartment shown in Tab. 9 portend different pixel event fractions for 
all cytokeratines between epidermis and extravascular compartment or vessel, 
respectively, but there is no indication for a difference between extravascular 
compartment and vessel. These findings support the qualitative interpretation derived 
from the heatmap. 
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Tab. 8.  Global ANCOVA table for clinical covariates and the cytokine group of single 
binders measured in affected psoriatic skin with sequential decomposition. 
Source of variation SSQ df MS F praw 
compartment 17.5 6 2.91 1221.3 2.57·10-70 
error 0.17 72 0.002   
 
 compartment 
 praw padj 
cytokeratin 2.49·10-21 2.49·10-21 
cytokeratin10 3.80·10-26 7.60·10-26 
cytokeratin14 7.10·10-28 2.13·10-27 
all cytokeratines 2.57·10-70  
 
Tab. 9. Pairwise comparison of cytokeratin pixel event fraction in three compartments 
of affected psoriatic skin. 
compartments SSQ df MS F pperm 
epidermal-extravascular 12.8 3 4.27 1794.4 <0.0001 
epidermal-vascular 13.4 3 4.45 1868.3 <0.0001 
extravascular-vascular 0.009 3 0.003 1.3 0.273 
error 0.172 72 0.002   
      
summary of dependent variables 
PEF of cytokeratin, cytokeratin 10, cytokeratin 14 in 3 compartments, N=9 
 
Another group of substantial interest is comprised by a family of three cell adhesion 
proteins CD62E, CD62L and CD62P also termed selectines. At the global level there is 
a clear association between pixel event fraction and compartment (Tab. 10) that is also 
reflected by the markerwise data. The pairwise comparisons by compartment shown in 
Tab. 11 indicate that the pixel event fractions for the selectin family are different 
between vascular and extravascular compartment or epidermis, respectively, but there 
is no indication for a difference between extravascular compartment and epidermis. 
Finally, there was no evidence of association with local symptom scores, PASI or 
percentage of affected body surface area for the selectin family. 
 
 
  
36 
 
Tab. 10.  Global ANCOVA table for clinical covariates and the selectin group of single 
binders measured in affected psoriatic skin determined with sequential decomposition. 
source of variation SSQ df MS F praw 
compartment 2.48 6 0.413 53.4 1.47·10-24 
error 0.296 72 0.004   
 
selectin marker compartment 
 
praw padj 
CD62E 6.52·10-8 1.31·10-7 
CD62L 3.87·10-3 3.87·10-3 
CD62P 1.47·10-11 4.42·10-11 
all selectines 6.26·10-21  
 
 
 
Tab. 11. Pairwise comparison of selectin pixel event fraction in three compartments of 
affected psoriatic skin. 
compartments SSQ df MS F pperm 
epidermal-extravascular 0.027 3 0.009 1.16 0.296 
epidermal-vascular 1.888 3 0.629 81.3 <0.0001 
extravascular-vascular 1.805 3 0.602 77.7 <0.0001 
error 0.557 72 0.008   
      
summary of dependent variables 
PEF differences of CD62E, CD62L, CD62P in 3 compartments,  N = 9 
 
 
 Topoproteomic coexpression data 
The coexpression pattern of affected psoriatic skin was analysed separately for the 
coexpression sets 00, 10 + 01 and 11. In each set the compartment term is highly 
significant at the global level (Tab. 12). At individual marker pair level, compartment 
factor is most relevant for the coexpression set 10 + 01. Adjustment for multiple testing 
via Holm Bonferroni reduces the number of marker pairs with significance drastically 
since the number of tests for coexpressed marker pairs is high (Tab. 13). 
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Tab. 12. Total number and percentage of marker pairs with a significant association 
between pixel event fraction and compartment. 
coexpressionset raw adjusted 
 N % N % 
00 833 73.9 200 17.7 
     
10 + 01 1782 82.3 1146 53.0 
     
11 664 58.9 171 15.2 
     
summary of dependent variables 
PEF of 1029 marker pairs in 4 coexpression sets; N = 9 
 
 
The association of pixel event fractions with clinical symptom scores is listed in Tab. 
13. For all models and coexpression sets compartment is a highly significant factor. 
This finding is in line with the summary of individual markers given in Tab. 12. There is 
no evidence of association between percentage of affected body surface area and 
PASI with pixel event fraction in each coexpression set. At the global level there is no 
association between local symptom scores and pixel event fraction in the coexpression 
set 00. In contrast, there is an association between the pixel event fraction and pruritus 
in the 10 + 01 and 11 coexpression sets. For induration the significance limit is 
exceeded to a minor extent. Similarly, there is a weak evidence for association 
between pixel event fraction and epidermal thickness in the coexpression sets 10 + 01 
and 11, which is absent in the 00 set. 
 
 
Tab. 13.  Global ANCOVA table for clinical covariates and 47 single binders measured 
in affected psoriatic skin. 
coexpression source of variation SSQ df MS F p 
clinical measurements 
 00 compartment 818.9 2258 0.362 8.33 0.0006 
  PASI 0.76 1129 0.00067 0.015 0.994 
  %BSA 2.53 1129 0.0022 0.052 0.886 
       
 10 + 01 compartment 1623.8 4328 0.375 63.3 <0.00001 
  PASI 11.7 2164 0.0054 0.913 0.419 
  %BSA 7.18 2164 0.0031 0.003 0.807 
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 11 compartment 42.7 2254 0.053 42.73 <0.00001 
  PASI 1.73 1127 0.0015 1.23 0.234 
  %BSA 1.04 1127 0.0009 0.740 0.712 
       
symptom measurements 
 00 compartment 818.9 2258 0.363 7.756 0.0015 
  induration 18.15 1129 0.016 0.348 0.542 
  scaling 11.83 1129 0.010 0.224 0.660 
  pruritus 9.97 1129 0.009 0.189 0.679 
 erythema 1.63 1129 0.0014 0.031 0.948 
        
 10 + 01 compartment 1623.8 4328 0.3752 0.375 <0.00001 
  induration 20.6 2164 0.0095 1.692 0.109 
  scaling 13.4 2164 0.0062 1.101 0.297 
  pruritus 28.5 2164 0.0131 2.342 0.038 
 erythema 16.0 2164 0.0074 1.31 0.211 
       
 11 compartment 119.9 2254 0.053 44.7 <0.00001 
  induration 2.19 1127 0.0019 1.633 0.097 
  scaling 1.48 1127 0.0013 1.105 0.318 
  pruritus 3.43 1127 0.0030 2.55 0.012 
erythema 1.30 1127 0.0012 0.968 0.425 
epidermal thickness 
 00 compartment 818.9 2258 0.362 8.898 0.0007 
  ETAPS 28.4 1129 0.025 0.617 0.460 
        
 10 + 01 compartment 1623.8 4328 0.375 66.3 <0.00001 
  ETAPS 27.2 2164 0.0126 2.22 0.055 
        
 11 compartment 119.9 2254 0.053 42.8 <0.00001 
  ETAPS 2.42 1127 0.0021 1.73 0.075 
          
summary of dependent variables 
PEF of 1029 marker pairs in 4 coexpression sets; N = 9 
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9.5 Difference of affected and unaffected psoriatic skin 
Unaffected psoriatic skin is clearly not the same as healthy skin. At least it is free of 
obvious clinical symptoms for psoriasis. In consequence, a hypothetical drug changing 
a marker response from the affected to unaffected value may be considered as 
successful. Therefore, the marker difference between affected and unaffected psoriatic 
skin may provide a useful model to select suitable markers to monitor a treatment 
effect of novel drugs. In the following section the response change between markers in 
affected and unaffected psoriatic skin for various groups of markers was analysed at 
the global level and for individual markers. 
 
 Skin cell count differences 
Counts of CD4, CD8, CD11c and CD68 positive cells were studied in affected and 
unaffected psoriatic skin. An example of the normalized CD4 cell count in dermis and 
epidermis is shown in Fig. 7. There is a clear decrease of the cell count from affected 
to unaffected psoriatic skin, even though there is some overlap of the CD4 positive cell 
count of different patients in both groups. In contrast, the CD68 cell count relation of 
unaffected and affected psoriatic skin is less clearly defined (Fig. 8). The Global 
ANCOVA table 14 for four skin cell count differences in two compartments provides 
evidence for a statistically significant intercept (praw = 9.50·10-45) and compartment (praw 
= 5.65·10-12). The significant intercept may be interpreted as a significant cell count 
difference between affected and unaffected psoriatic skin. The sequential 
decomposition at the individual marker level supports the before mentioned result. 
However, it should be kept in mind that the before mentioned p-values derived from 
sequential decomposition are affected by inflation of the type I error. Therefore an 
adjustment for multiple testing is necessary. Both the raw and the adjusted p-values for 
the intercept of CD4, CD8 and CD11c count provide evidence for a significant mean 
difference between both psoriatic skin states, compartment is also a relevant factor for 
the before mentioned markers. For CD68 positive cells all p-values exceed the 
significance limit of 0.05.  
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Fig. 7. Normalized count of CD4 positive cells in affected and unaffected psoriatic skin 
of 15 patients (mean of three measurements). 
 
Tab. 14. Global ANCOVA table for the cell count differences between affected and 
unaffected psoriatic skin with compartment covariate. 
 
source of variation          SSQ df    MS                      F praw 
Intercept   1807.7   4  451.9 155.4 9.50·10-45 
compartment   221.6   4   55.4 19.0 5.65·10-12 
error        325.8 112 2.9   
 
skin cell count intercept compartment 
 
praw padj praw padj 
CD4    1.99·10-14 7.98·10-14 1.03·10-6 4.10·10-6 
CD8    3.69·10-12 7.37·10-12 3.58·10-3 7.16·10-3 
CD11c  5.16·10-14 1.55·10-13 3.15·10-4 9.45·10-4 
CD68   8.76·10-1 8.76·10-1 1.65·10-1 1.65·10-1 
all    9.50·10-45  5.65·10-12  
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Fig. 8. Count of CD68 positive cells in affected and unaffected psoriatic skin of 15 
patients (mean of three measurements). 
 
 
 
There was no evidence for an association between cell count differences and global 
symptom scores. This finding for the differences between affected and unaffected 
psoriatic skin corresponds to the findings for affected psoriatic skin listed in Tab. 4. 
Similar to the global symptom score, no evidence of association between cell count 
differences and local symptom scores was found. In contrast to the factor 
compartment, there is no evidence of an association between the cell count differences 
and the epidermal thickness of affected psoriatic skin (Tab. 15).  
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Tab.15. Global ANCOVA Table for the cell count differences between affected and 
unaffected psoriatic skin with epidermal thickness of affected psoriatic skin covariate. 
 
source of variation          SSQ df    MS                      F padj 
compartment 221.6 4 55.4 19.9 <0.00001 
ET(APS) 25.4   4   6.3 2.28 0.108 
      
summary of dependent variables 
CD8, CD8, CD11c, CD68 cell count differences in dermis and epidermis; N = 15 
 
 
 Skin cytokines and psoriasis relevant mediators 
Eight different cytokines and psoriasis relevant mediators were studied in affected and 
unaffected psoriatic skin. An example of the relative CCL27 expression in affected and 
unaffected psoriatic skin in 15 patients is shown in Fig. 9. There is a clear increase in 
relative expression from affected to unaffected psoriatic skin. Similar to the CD4 cell 
count (Fig. 7) there is an overlap of the data from both skin states, but unlike to the cell 
counts it is not possible to distinguish between different cell compartments in this type 
of experiment. 
 There is strong evidence for a significant difference between cytokine 
expression in affected and unaffected psoriatic skin (praw = 8.20·10-64) and for an 
association with epidermal thickness of affected psoriatic skin (praw = 9.62·10-11) at the 
global level (Tab. 16). The association with affected skin is reflected by the sequential 
decomposition at the level of individual skin cytokines. When adjusted for multiplicity, 
the intercept p-values range from 4.16·10-11 for IL-17A to 1.28·10-7 for IL-10 and 
CCL27. A significant association between differential cytokine expression and 
epidermal thickness appears to exist for the cytokines IL-22, IL-17A and CCL27. This 
finding is supported graphically by Fig. 10. The diagnostic subjects plot shown in Fig. 
11 provides information on the reduction of the sum of squares per subject. Most bars 
are positive and therefore the samples contribute to low p-values.  
 Both sequential decompositions and type-III decompositions support the before 
mentioned association between epidermal thickness of affected psoriatic skin and 
expression of cytokines and mediators. No association was found for the local and 
global symptom scores. 
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Fig. 9. CCL27 expression in affected and unaffected psoriatic skin of 15 patients (mean 
of three measurements). 
 
Tab. 16. Global ANCOVA Table for the differences of skin cytokines and mediators 
between affected and unaffected psoriatic skin with epidermal thickness covariate. 
source of variation          SSQ df    MS                      F praw 
Intercept   1957.4   8  244.5 244.5 8.20·10-64 
ETAPS 84.4   8  10.5 10.5 9.62·10-11 
error        104.0 104 1.00          
 
skin biomarker       Intercept ETAPS 
 praw padj praw padj 
IL-22   1.78·10-9 7.14·10-9 4.86·10-3 0.029 
IL-20   4.71·10-10 2.35·10-9 3.74·10-2 0.112 
IL-10   4.27·10-8 1.28·10-7 6.86·10-1 1.000 
IFN-γ 3.00·10-10 2.10·10-9 1.26·10-2 0.063 
IL-17A  5.20·10-12 4.16·10-11 4.28·10-4 0.003 
IL-23A 5.75·10-7 5.75·10-7 2.29·10-2 0.091 
CCL27 4.32·10-8 1.28·10-7 2.04·10-4 0.001 
S100A7 3.36·10-10 2.10·10-9 9.03·10-1 1.000 
all 8.20·10-64  9.62·10-11  
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Fig. 10. Influence of individual cytokines and psoriasis mediators on the Global 
ANCOVA test statistic. 
 
 Topoproteomic single binder differences 
Differences between pixel event fractions were analysed for 47 markers in the 
epidermal, extravascular and vascular compartments of affected psoriatic skin. At the 
global level, both intercept and compartment are significant (Tab. 17). According to the 
sequential decomposition for each marker, 18 raw p-values for intercept (38%) and 32 
raw p-values for the factor compartment (68%) are smaller than 0.05. After adjustment 
according to the Bonferroni-Holm procedure, 4 and 15 markers corresponding to 9% 
and 32%, respectively, remain below the limit of significance.  These are CD29, 
CD62L, CD62E and CD7 for intercept and c-myc, CD207, CD29, CD62L, CD4, CD44, 
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CD45, CD45RA, CD62E, CD68, CD8, HLA-DQ, HLA-DR, propidium iodide and 
RORγ/NR1F3 for compartment. Two diagnostic plots are presented below. The 
influence of each marker on the sum of squares can be seen in Fig. 12. Clearly, this 
plot differs in some aspects from the corresponding plot for affected skin Fig. 5.  For 
example, CD44 contributes most to the reduction of the sum of squares in the plot for 
the differences between affected and unaffected skin, whereas it is of minor importance 
in the plot for affected psoriatic skin. This is of marked contrast to all cytokeratin 
markers showing the opposite characteristics.  The sample plot shown in Fig. 13 
visualizes the reduction of the sum of squares samples per sample. This suggests that 
almost all samples fit to the model since positive bars lead to a decrease of p-values, 
negative bars to an increase. 
 The pixel event fraction differences of single binders between affected and 
unaffected psoriatic skin appear to be associated with PASI at the global level, but not 
with the percentage of affected body surface (Tab. 18). The epidermal thickness of 
affected psoriatic skin is not associated significantly with the pixel event fraction 
differences. Out of the local symptom scores, only pruritus is significantly associated 
with the before mentioned differences. A low p-value exceeding somewhat the 
significance limit was also found for the factor induration. It is possible to compare the 
influence of each factor in the sequential decomposition at the level of the individual 
markers (Fig. 14). The segments of this bar plot show the relative extra sum of squares 
contribution of each factor to the model sum of squares. The model sum of squares for 
each marker has been normalized to facilitate a comparison of different markers. 
Clearly, the compartment factors dominate for most markers. However it should be 
kept in mind that a sequential decomposition is shown and compartment is the first 
term. For a detailed interpretation of this graphical representation, however, the 
significance of each factor should be considered at the individual marker level. Further, 
a reasonable hierarchy should be given to obtain a meaningful interpretation from this 
type of analysis. 
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Fig. 11. Influence of individual samples on the test statistic for skin cytokines and 
psoriasis mediators. 
 
Tab. 17.Global ANCOVA table for the PEF differences between affected and 
unaffected psoriatic skin with compartment covariate with sequential decomposition. 
 
source of variation          SSQ df MS F praw 
Intercept 2.42 47 0.0515 3.73 3.10·10-15 
compartment 10.0 94 0.107 7.74 1.26·10-71 
error 15.5 1128 0.013   
 
 
marker intercept compartment 
 
praw padj praw padj 
actin 2.89·10-1 1.000 6.97·10-1 1.000 
c-myc 6.23·10-1 1.000 7.90·10-4 0.027 
CCR4 1.50·10-1 1.000 2.85·10-2 0.569 
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CD11a 8.85·10-3 0.345 1.43·10-3 0.330 
CD11c 5.93·10-1 1.000 3.16·10-2 0.088 
CD13 2.68·10-1 1.000 6.05·10-2 1.000 
CD138 1.40·10-1 1.000 2.59·10-1 1.000 
CD15 1.47·10-2 1.000 1.49·10-1 1.000 
CD163 7.49·10-1 1.000 4.23·10-2 0.803 
CD1a 2.90·10-2 0.955 2.0710-3 0.066 
CD2 3.51·10-1 1.000 2.17·10-3 0.067 
CD207 3.19·10-3 0.131 1.40·10-7 <0.001 
CD25 1.10·10-2 0.418 5.45·10-2 0.981 
CD26 3.64·10-2 1.000 1.75·10-2 0.386 
CD29 4.42·10-4 0.019 2.13·10-6 <0.001 
CD31 4.17·10-1 1.000 8.90·10-1 1.000 
CD3 1.40·10-2 0.517 6.30·10-2 1.000 
CD62L 1.57·10-5 <0.001 1.03·10-3 0.034 
CD4 1.30·10-2 1.000 2.28·10-5 0.001 
CD44 3.18·10-2 1.000 8.14·10-5 <0.001 
CD45 6.49·10-1 1.000 2.70·10-5 0.001 
CD45RA 1.00·10-1 1.000 6.01·10-4 0.021 
CD45RO 1.34·10-1 1.000 2.47·10-3 0.074 
CD49f 3.04·10-3 0.127 1.80·10-2 0.386 
CD54 6.75·10-1 1.000 9.06·10-1 1.000 
CD56 6.82·10-2 1.000 7.3510-3 0.184 
CD62E 7.08·10-5 0.003 1.12·10-5 <0.001 
CD62P 1.05·10-1 1.000 1.10·10-1 1.000 
CD68 4.66·10-1 1.000 2.09·10-4 0.008 
CD7 8.49·10-7 <0.001 7.52·10-3 0.184 
CD8 2.57·10-1 1.000 3.02·10-4 0.011 
CD90 4.91·10-1 1.000 3.61·10-1 1.000 
CLA 1.60·10-2 0.559 6.24·10-3 0.161 
collagen type IV 7.51·10-1 1.000 8.06·10-2 1.000 
cytokeratin 7.02·10-1 1.000 9.98·10-1 1.000 
cytokeratin10 8.75·10-1 1.000 9.91·10-1 1.000 
cytokeratin14 5.09·10-1 1.000 8.52·10-2 1.000 
Factor XIII subunit A 8.45·10-1 1.000 9.09·10-2 1.000 
Foxp3 2.46·10-3 0.106 7.49·10-2 1.000 
HLA-DQ 1.50·10-1 1.000 2.67·10-4 0.010 
HLA-DR 4.13·10-1 1.000 5.99·10-3 0.022 
Ki67 9.62·10-1 1.000 2.22·10-1 1.000 
propidium iodide 7.89·10-2 1.000 1.23·10-4 0.005 
RORγ/NR1F3 4.90·10-1 1.000 4.43·10-3 0.016 
STAT3 2.79·10-2 0.949 3.32·10-2 0.090 
TIA1 3.55·10-1 1.000 1.23·10-1 1.000 
vimentin 6.67·10-3 0.266 2.57·10-3 0.075 
all 3.10·10-15  1.26·10-71  
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Fig. 12. Marker plot for difference in pixel event fraction between affected and 
unaffected psoriatic skin of each marker. 
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Fig. 13. Sample plot for pixel event fraction of single binder differences between 
affected and unaffected psoriatic skin. 
 
 
  
50 
 
Tab. 18. Global ANCOVA table for clinical covariates and 47 single binder pixel event 
fraction differences between affected and unaffected psoriatic skin. 
 
source of variation           SSQ df MS F pperm 
clinical measurements      
compartment 10.0 94 0.106 8.11 0 
PASI 1.33 47 0.028 2.15 0.019 
%BSA 0.71 47 0.015 1.14 0.309 
      
symptom measurements      
compartment 10.0 94 0.106 8.34 <0.00001 
induration 0.98 47 0.021 1.64 0.098 
scaling 0.71 47 0.015 1.17 0.266 
erythema 0.64 47 0.014 1.06 0.397 
pruritus 1.17 47 0.025 1.94 0.040 
      
epidermal thickness      
compartment 10.0 94 0.0107 7.85 0 
ETAPS 0.856 47 0.0182 1.34 0.193 
      
summary of dependent variables 
PEF of 47 markers in 3 compartments (see Tab. 17); N = 9 
 
 
 
 
The Global ANCOVA table for the cytokine family pixel event fraction of affected 
psoriatic skin (Tab. 8) differs in some aspects from the corresponding table for the pixel 
event fraction differences between affected and unaffected psoriatic skin (Tab. 18). In 
the former table compartment is a significant factor, in the latter table neither intercept 
nor compartment is statistically significant. This suggests that the mean cytokeratin 
concentration does not differ in affected and unaffected psoriatic skin. This view is also 
supported by the heatmap shown in Fig. 3. The thickness of the epidermis in affected 
psoriatic skin exceeds the one of unaffected skin. Therefore the total amount should be 
different. 
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Fig. 14. Sequential decomposition of the model sum of squares for pixel event fraction 
difference between affected and unaffected psoriatic skin of 47 markers. 
 
For the selectin group of proteins a different pattern emerges (Tab. 19).  Both factors 
intercept and compartment are significant. At the level of individual markers, CD62E 
and CD62L are significant after adjustment for multiple testing. There was no 
noticeable association between pixel event fraction differences of selectines and 
epidermal thickness. Pairwise comparisons pixel event fraction change between 
affected and unaffected skin for the selectin family suggest a significant difference of 
between vessel and both extravascular compartment and epidermis, but no difference 
between the latter compartments (Tab. 21). 
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Tab. 18.  Global ANCOVA table for the cytokeratin group of single binders measured in 
affected psoriatic skin. 
 
source of variation           SSQ df MS F praw 
Intercept 0.0026 3 0.00085 0.180 0.909 
compartment 0.0011 6 0.00031 0.666 0.677 
error 0.342 72 0.00476   
      
summary of dependent variables 
PEF differences of cytokeratin, cytokeratin 10 and cytokeratin 14 in 3 compartments;  N = 9 
 
 
 
Tab. 19. Global ANCOVA table for the pixel event fraction difference between affected 
and unaffected psoriatic skin of the selectin group with sequential decomposition. 
 
source of variaton SSQ df MS F praw 
Intercept 0.429 3 0.143 12.4 1.26·10-6 
compartment 0.651 6 0.109 9.42 1.27·10-7 
error 0.830 72 0.012   
 
 
selectin markers intercept compartment 
 
praw padj praw padj 
CD62E 7.08·10-5 1.42·10-4 1.13·10-5 3.39·10-5 
CD62L 1.57·10-5 4.71·10-4 1.03·10-3 2.06·10-3 
CD62P 1.05·10-1 1.05·10-1 1.10·10-1 1.10·10-1 
all 1.26·10-6  1.27·10-7  
 
 
Tab. 20. Pairwise comparisons of selectin pixel event fraction differences. 
compartments SSQ df MS F pperm 
epidermal-extravascular 0.039 3 0.013 1.11 0.307 
epidermal-vascular 0.482 3 0.160 13.9 <0.001 
extravascular-vascular 0.457 3 0.152 13.2 <0.001 
error 0.830 72 0.012   
      
summary of dependent variables 
PEF differences of CD62E, CD62L, CD62P in 3 compartments;  N = 9 
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 Topoproteomic coexpression data 
The coexpression pixel event fraction differences between affected and unaffected 
psoriatic skin were analysed separately for the coexpression sets 00, 10 + 01 and 11. 
At the level of individual marker pairs, there is a decrease of the percentage of marker 
pairs with a significant mean change from set 11 over 10 + 01 to 00. Adjustment for 
multiple testing via Holm Bonferroni leads to a strong reduction of significant marker 
pairs since the number of coexpressed marker pairs is high. This is in line with the 
analysis of coexpression PEF for affected skin (Tab. 12). 
 
Tab. 21.  Total number and percentage of coexpressed marker pairs with a significant 
mean pixel event fraction change between affected and unaffected psoriatic skin. 
 
coexpressionset raw adjusted 
 N % N % 
00 176 15.6 1 0.1 
     
10 + 01 500 23.1 32 1.5 
     
11 441 39.1 12 3.6 
 
 
The data listed in Tab. 21 suggest that only a few marker pairs of the co-expression 
sets 10 + 01 and 11 are suitable for the distinction of affected and unaffected psoriatic 
skin whereas hardly any individual marker pair of coexpression set 00 yields significant 
information on the difference between affected and unaffected psoriatic skin. In other 
words, the absence of simultaneous marker pair fluorescence does not provide much 
information on disease status. Marker pairs with a statistically significant intercept 
comprise mainly pairs formed by actin, CD2, CD11c, CD13, CD138, CD207, CD29, 
CD44, CD49f, CD62E, CD62L, CD7, CLA, collagen type IV, cytokeratin 10 and 14, 
Foxp3, HLA-DQHLA-DR, RORγ/NR1F3, STAT3 and vimentin.  
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10. Discussion 
10.1 Relation between biomarkers and psoriasis 
Disease related biomarkers play an increasingly important role in the development of 
novel medications. For example, they may correlate longitudinally with disease 
progression, may highlight the effect of a medical intervention or serve as surrogate 
endpoints in clinical studies [15-17]. For these reasons it is advantageous to have a 
series of specific and validated biomarkers at our disposal. In psoriasis, each treatment 
can interfere with several aspects of the psoriatic lesion including aspects of the 
immune system, epidermal proliferation, and altered keratinocyte differentiation. By 
means of the corresponding biomarkers it is possible to detect such changes. 
Therefore, in sub-study A histological and immunohistological changes and changes of 
the expression profile of psoriasis relevant mediators in the skin as well as psoriasis 
relevant mediators in the blood were analysed. In Part B of the Sub-study spatially 
resolved topoproteome changes in skin were assessed by means of biomarkers. 
 
 Suitable biomarkers for psoriasis monitoring 
Using the difference between affected and unaffected psoriatic skin as a model, a 
series of biomarkers showing evidence for an association with the before mentioned 
disease was determined (Tab. 14, 16, 17). For a small sample size the skin cell counts 
of CD4, CD8 and CD11c, the cytokines and mediators IL-10, IL-20, IL-22, IFN-γ, IL-
17A, IL-23A and S100A7 were found to be clearly different in affected and unaffected 
psoriatic skin. In blood IL-8, IL-22 and CCL 27 are promising for a distinction. This also 
indicates that the methods themselves and the type of biomarkers chosen were 
appropriate for analysis of psoriatic skin. For topoproteome analysis the markers CD31, 
CD62L, CD62E and CD7 are recommendable since they show a clear change between 
both types of skin when averaged over all compartments. A more detailed inspection 
shows that in sub-study A almost all markers for skin cell count, cytokines and 
mediators are significantly different in affected and unaffected psoriatic skin, whereas 
in sub-study B only about 9% of the single binders and 0.1 to 3.6 % coexpression pairs 
are significantly different. However, additional markers may be used for monitoring of 
psoriasis provided that a specific skin compartment is selected. This follows from the 
finding that the change between affected and unaffected psoriatic skin is associated 
with the factor compartment for 32% of the single binders.  
 It should be noted that both sub-studies were evaluated with the same statistical 
method and the same assumptions. All before mentioned markers were evaluated with 
adjustment for multiple testing at α = 0.05. Nevertheless the percentage of markers 
changing upon the disease status is different in both studies.  Therefore, the origin of 
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this finding must be somewhere else. First, most markers used in both studies are 
biochemically different and cannot be compared directly with each other in most cases. 
Second, the ratio between marker variance and marker difference between affected 
and unaffected skin appears to be somewhat more favourable for markers in sub-study 
A. Finally, the ratio between sample size and number of markers is much more 
balanced in sub-study A. This is of particular relevance for large number of 
coexpression data. A more liberal limit of significance for the Holm-Bonferroni 
procedure would extend the before mentioned list. Details are discussed in the section 
referring to study design aspects.  
 
 Special marker groups 
Testing certain groups of markers can be accomplished easily with Global ANCOVA. 
Two special marker groups, cytokeratines and selectines, were studied in more detail 
in order to investigate their relation to psoriasis and their distribution in the different skin 
compartments.  
 The distinction of the different skin compartments by means of cytokeratin pixel 
event fraction in the heatmap (Fig. 3) is clearly reflected by the results of the 
corresponding pairwise compartment comparisons. The pixel event fractions in the 
epidermal and extravascular compartment and in epidermal and vascular compartment 
are significantly different. This is just the opposite of the extravascular and vascular 
regions of the skin (Tab. 9). The compartment term of the pixel event fraction 
measured for affected psoriatic skin of the cytokeratin group comprising cytokeratin, 
cytokeratin 10 and cytokeratin 14 are highly significant. Surprisingly, findings are 
different when cytokeratin pixel event fraction changes between affected and 
unaffected psoriatic skin are analysed (Tab. 18). Neither the intercept indicating a 
mean difference nor the compartment term is significant. An inspection of the data 
suggests that the fraction of pixels indicating presence of cytokeratines is almost 
identical in affected and unaffected epidermis. Usually the thickness of the epidermis is 
much higher in samples of affected skin than in unaffected skin and this leads to the 
well known high abundance of cytokeratines in psoriatic skin. 
 The merging of CD62E, CD62L and CD62P into the selectin group may be 
justified by the similarity of the structure and biological function. The similarity led to the 
hypothesis of pan-selectin antagonism meaning that a single antagonist may bind to all 
three selectines to perform its pharmacological action [18]. Compartment is a 
significant factor for the pixel event fraction of the selectin family - an analogy to the 
cytokeratines. Pairwise testing suggests that the extravascular and epidermal 
56 
 
compartments and further the epidermal and vascular compartments are significantly 
different, whereas no difference was found between epidermal and extravascular 
compartments (Tab. 11). For the pixel event fraction change between affected an 
unaffected skin adjusted p-values close to or below the significance limit were found at 
individual level for the selectin family (Tab. 20). This suggests that selectins might play 
a role in psoriasis pathology. Pairwise testing for compartment dependence of selectin 
pixel event fraction difference in affected and unaffected psoriatic skin reveals a pattern 
for the p-values similar to the corresponding analysis of affected psoriatic skin (Tab. 11, 
21). For both data sets a comparison of the epidermal and extravascular compartments 
provides no evidence of a difference. This is in marked contrast to the other 
compartments. The findings are in line with the literature describing an increased 
selectin expression of in vessel of affected psoriatic skin [19]. 
 
 Association between biomarkers and clinical covariates 
As described above various types of clinical assessments have been published for 
psoriasis. Among the most popular measures are the percentage of affected body 
surface area, PASI and PGA scores [6]. Local scales comprise epidermal thickness or 
symptom scores such as induration, scaling, erythema and pruritus.  
 It should be noted that single markers measured only in a small group of 
patients are not sufficiently meaningful to establish an association with clinical 
symptoms in a small group of patients. However, the Global ANCOVA overcomes this 
limitation and enables the investigation of the relation of clinical symptoms with groups 
of markers. For this purpose type-III decomposition was used throughout. 
 Inspection of the patient baseline characteristics Tab. 2 suggests that PGA is 
not sensitive enough to discriminate between patients with mild or moderate psoriasis 
since PGA adopts a value of 3 for all sub-study patients. The whole group of blood 
biomarkers is associated with PASI and percentage of affected body surface area 
whereas no evidence for an association between local symptom scores or epidermal 
thickness was found, respectively (Tab 3).  
 The group of skin cytokines and psoriasis relevant mediators appears to be 
associated with percentage of affected body surface area and epidermal thickness of 
affected psoriatic skin; an association with local symptom scores was not evident (Tab. 
5). The group of 47 markers used for topoproteome analysis is associated with the 
epidermal thickness of affected psoriatic skin and the local symptom score pruritus 
(Tab. 7).  
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As described above, both marker values in affected psoriatic skin and marker changes 
between affected and unaffected psoriatic skin were studied. A comparison suggests 
that there is some correspondence of the association between both of the before 
mentioned data and clinical symptoms. For example, the p-values for the association of 
symptom scores or epidermal thickness with the pixel event fraction in affected 
psoriatic skin (Tab. 7) resemble the corresponding values for the change of the pixel 
event fraction between affected and unaffected psoriatic skin (Tab. 18). 
 
 Limitations 
This is an exploratory study and the results presented here should be validated in a 
further step. On the one hand, the sample size is small; on the other hand patients 
were limited to mild and moderate psoriasis. In severe psoriasis findings may differ. 
Therefore, additional studies are recommendable to obtain information on validity and 
generalizability. 
 
10.2 Statistical methodology 
Multi-Epitope-Ligand-Cartography provides a detailed map of protein expression within 
a skin sample. At each a pixel fluorescence signal is detected that is believed to 
provide information on the presence of a target protein. These data were obtained from 
multiple measurements on the same object. In consequence, they cannot be regarded 
as independent. This is also supported from a dermatological point of view. The 
distinction of compartments implies some kind of similarity within these regions of the 
skin. The lack of independence leads to reduction of the effective sample size and 
requires the use of statistical methods taking into account the clustered data structure. 
One possibility to analyse such data consists in the application of the generalized 
estimating equations. This procedure provides the possibility to estimate mean 
treatment effects without the requirement of a detailed modelling of the covariance. A 
quite large number of clusters – here number of biopsies or corresponding images – is 
required to provide reliable results when the working covariance is not specified 
accurately [20]. Another possibility is the application of mixed models with a detailed 
modelling of the distance dependent correlation in two dimensions. Here a third way of 
analysis has been used. A simple summary measure termed pixel event fraction was 
calculated to reduce the computational complexity. The method enables a distinction of 
skin compartments using certain markers as a probe, it does not suffer extensively 
from a varying size of the skin biopsies and, finally, it may be interpreted as some kind 
of measure for the concentration of the target of the corresponding biomarker in the 
skin. This facilitates the interpretation compared to PEN – a quantity depending on 
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fluorescence intensity and compartment size at the same time. In this respect 
topoproteomic analysis can provide a more detailed view than immunohistology. 
 The transformation of complex fluorescence data into a simple summary 
measure facilitates the application of a variety of statistical methods for data analysis. 
Here, the Global ANCOVA method has been used [7, 8]. This method focuses on 
marker groups with coordinated changes according to the disease status or treatment. 
It enabled the statistical analysis of a variety of data relevant to characterize psoriasis 
within a single consistent framework. In addition, the procedure enabled the 
consideration of skin compartments and an association between markers and clinical 
covariates. This led to the identification of a series of marker groups associated with 
the disease status or symptom scores even though the sample size was quite small. 
This may be performed in a more systematic way using a hierarchy of null hypotheses 
[9, 21]. The flexibility of the R-language makes the analysis of treatment effects rather 
simple by formulating models with treatment effects such as  
 
PEF ~ compartment + treatment  
 
Adjustment for baseline or other covariates is also possible. Models for longitudinal 
data analysis are currently not implemented. Clinical studies of psoriasis are often 
longitudinal studies and therefore the Global ANCOVA package may benefit from an 
extended range of applications. 
 The statistical analysis of pixel event fractions can be performed at an even 
simpler level but there are several pros and cons to be considered.  A reasonable 
method of choice is a separate conventional ANCOVA for each marker and each 
compartment. An argument for this approach is the simplicity, but there are also clear 
disadvantages. This approach lacks the possibility of marker grouping to improve 
statistical power and the joint modelling of skin compartments. Further, the high 
number of statistical tests leads to a substantial α-inflation. The even simpler approach 
of using follow-up data alone is known to be biased and inefficient, in other words there 
may be an enlarged variance of the estimated treatment effect [22]. This is of particular 
importance when there is substantial scatter in the baseline data. Exactly this appears 
to be a general feature of many marker data in affected psoriatic skin and the 
randomization of a small sample of patients may lead to an imbalance of baseline data 
(Fig. 2, 3, 7-9). The use of changes from baseline may be more efficient depending on 
the correlation of follow-up and baseline data. In any case ANCOVA approaches 
provide more power, an important issue when the experimental method requires a 
considerable effort and sample size is small. 
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 Implications for study design 
In the following section statistical aspects of clinical trials involving biomarker data are 
discussed. The putative design consists in a parallel trial with two treatment groups 
where biopsies are taken at baseline and follow-up to measure biomarkers. For 
experimentally demanding measurements sample size calculations are an important 
aspect to limit the experimental burden without limiting the possibility of finding true 
positives. This leads immediately to a conflicting situation when many biomarkers are 
measured as the dramatically increasing number of false positives has to be controlled 
in an adequate manner [23, 24].The necessity to control for false positive can be seen 
easily from the topoproteomic data sets. The probability of observing one or more false 
positive is 100 × (1-α)n where marker independence was assumed  to simplify the 
estimation. The conventionally accepted significance limit 0.05 for α and n = 47 and 
1029 for the number of single binders and coexpression sets, leads to a probability of 
91% and 100% for false positives. This result implies that no conclusions can be drawn 
without controlling multiplicity due to the high probability that one or even all positives 
are false positives. For a small number of markers such as the immunohistologic 
markers studied here, multiplicity is a minor issue, provided that the markers are not 
primary endpoints of a clinical trial. The adjustment of p-values leads to a decrease of 
power. This might explain the finding that the percentage of markers showing a 
significant difference between affected and unaffected psoriatic skin is much smaller for 
single binders and coexpression marker pairs than for the small number of histologic 
and immunohistologic markers. 
 To design studies leading to meaningful results, sample size estimations are 
required. This will be presented for two different approaches of analysis, conventional 
ANCOVA and Global ANCOVA in order to enable further insight into the advantage of 
Global ANCOVA. 
 For conventional ANCOVA the sample size per group is given approximately by 
the equation below [25]. 
 
> = 2 ?@∆@ 1 − C@#DE/@ + DG$@ 
 
n = number of subjects per group ? = standard deviation  ∆ = minimum difference to be detected 
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C = correlation between baseline and follow-up data DE/@ = 1.96 for α = 0.05 DG = 0.84 for β = 0.2 
 
It should be kept in mind that this approximation is less accurate for small samples. In 
this situation the sample size should be increased by one subject. An example of the 
sample size for a single marker is shown below for different ratios of standard deviation 
and difference to be detected (Tab. 23). When multiple markers are studied, smaller 
limits of α compatible for multiple testing must be used. 
 
Tab. 23. Sample size per group for a single marker measured at baseline and follow-
upa). 
 follow-up only ANCOVA 
  ρ = 0.25 ρ = 0.5 ρ = 0.75 
∆/σ  N N N 
1 16 16 13 8 
0.75 28 27 21 16 
0.5 65 59 47 28 
a)for α = 0.05 and β = 0.2. 
 
The table suggests that only those markers should be considered that ensure a ratio 
∆/σ not much smaller than 1 in order to avoid large sample sizes. It can be seen that 
ANCOVA is much more efficient than a simple univariate test of follow-up data when 
the correlation between baseline and follow-up data is high. In this situation there is a 
clear reduction of sample size. When the number of markers increases, there is also a 
strong increase in the required sample size to maintain a sufficiently high power (Fig. 
15). It is necessary to limit the number of markers in order to keep the sample size 
small. Further, it is of advantage to concentrate on markers with a high correlation 
between baseline and follow-up data and a favourable ratio between standard 
deviation and expected minimum difference to be detected. 
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Fig. 15.Sample size per group for conventional ANCOVA analysis of multiple markers 
using the Bonferroni method to control for multiplicity (top: ∆/σ = 1, bottom: ∆/σ = 0.5; 
correlation ρ = 0.25 (top line), 0.50 (middle line) and 0.75 (bottom line); α = 0.05 and β 
= 0.2). 
 
The sample size calculations above enable the planning of a putative parallel study. A 
reasonable setting might be a randomization ratio of 1:1 between active compound and 
placebo and the detection of an improvement corresponding to the marker difference 
between affected and unaffected psoriatic skin.  
 Skin cytokines, cell counts and mediator data measured in sub-study A exhibit 
typically ratios ∆/σ between 2.5 and 1.3, except for CD68 which is substantially smaller. 
Assuming a correlation between baseline and follow-up of 0.5, a sample size of less 
than 13 patients per group is sufficient for a single skin biomarker or for gene 
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expression. For a typical setting of 5 biomarkers, up to 17 samples per group are 
required (Fig. 15 top). This sample size decreases substantially when ρ exceeds 0.5.  
 For the single binder PEN data the ratios σ/∆ are much more variable due to the 
heterogeneity of the markers under investigation. Thus there is large scatter in the ratio 
∆/σ required for sample size calculation. When markers with low abundance in a 
specific compartment or small differences between affected and unaffected psoriatic 
skin are excluded, ∆/σ ranges typically from 1.3 to 0.8 depending on compartment. This 
suggests that about 13 samples per group are a reasonable magnitude for the study of 
a single binder for ∆/σ=1. This sample size increases substantially, when the number of 
markers increases. For example, 20 samples per group are required for 10 markers 
and 23 for 25 markers. Again, this sample size decreases substantially when ρ 
exceeds 0.5 and ANCOVA is used for statistical analysis. On the other hand it should 
be noted that the sample size increases drastically, when the minimum change to be 
detected decreases. For example, when a putative drug is suspected to be able to 
improve the marker values only 50% of the difference between affected and unaffected 
skin, the sample size is given by the curves plotted in the bottom of Fig. 15. This clearly 
points out that markers should be selected carefully instead of measuring large 
heterogeneous libraries. In this respect, the markers with low p-values listed in Tab. 18 
provide a good starting point. These markers provide a reasonable ratio ∆/σ. An 
additional advantage consists in a restriction of the number of hypotheses to be tested. 
According to the Global ANCOVA approach different scenarios may lead to a rejection 
of the global null hypothesis that no marker of the groups shows a treatment effect. 
Either, there are only a few strongly responding markers or many weakly responding 
markers. This feature is reflected by the Global ANCOVA sample size. Numerical 
simulations are required as no simple sample size formula has been derived till now. 
The simulations require a detailed specification of the model, the number of 
compartments, the number of markers and the putative response to the treatment. 
Such detailed calculations are beyond the scope of this study. Thus, only a rather 
simple example is presented here. The simulation scenario consists of a set of 5, 10 
and 20 markers and it was assumed for simplicity that a certain fraction of these 
markers showed a treatment affect ∆  whereas the remaining ones did not show any 
treatment effect (∆ = 0). Both marker groups were assumed to show the same standard 
deviation σ. Result are displayed graphically for the ratios ∆/σ = 1.0 and 0.75 obtained 
from 5000 normally distributed random samples each (Fig. 16). There is a strong 
decrease in sample size if the number of markers increases or if the fraction of 
responding markers increases. As expected, the sample size decrease if the ratio 
σ/∆=1.0 decreases. However, it should be noted that the sample size shown below 
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may be affected seriously by α-inflation. Therefore the actual sample size to be 
selected should be clearly higher. At the level of individual markers sample size 
simulations may be performed as well and in this case it is possible to adjust for 
multiplicity by means of the Bonferroni-Holm procedure. 
 
Fig. 16. Sample size per group for Global ANCOVA analysis of multiple markers for (α 
= 0.05 and β = 0.2; top: ∆/σ = 1, bottom: ∆/σ = 0.75 for responding markers; number of 
markers 5 (top line), 10 (middle line) and 20 (bottom line) α = 0.05 and β = 0.2). 
 
The results of the present sub-study suggest two different scenarios for the conduct of 
biomarker studies. In the explorative scenario the missing of markers may be regarded 
as a more severe consequence than the appearance of a few false positive markers 
when the main intent of the trial is the finding of novels related to a disease. Therefore, 
a moderately increased sample size and a relaxed α for multiple testing appear to be a 
reasonable approach provided that the results are validated in a subsequent step.  
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In a confirmative scenario false positive results are objectionable. Therefore, relaxed α 
is not a good choice. Instead, a moderately increased sample size and the restriction to 
a small number of validated markers is recommendable. The markers should have a 
favourable ratio ∆/σ in order to be able detect treatment effects. Global ANCOVA 
appears to be useful when clearly defined marker groups such as an efficacy or a 
safety data set can be defined. In this situation the global analysis of groups provides 
more power than individual tests for each marker. Selected markers to answer specific 
research problems should be used instead of heterogeneous libraries in order to 
minimize multiple testing. This is of particular importance for the coexpression 
experiments where the combinatorial explosion of the number of hypothesis tests for 
individual marker pairs requires a drastically increased sample size. On the other hand, 
coexpression analyses may provide valuable biological information since the 
simultaneous expression of proteins at the same location in the skin may provide hints 
to establish biological function. To escape from this dilemma, hypothesis tests should 
be restricted to a small quantity of psoriasis related marker pairs exhibiting a sufficiently 
small variance. All hypotheses to be tested should be specified in advance in a 
statistical analysis plan. 
 
11. Conclusion 
To sum up, skin and blood samples of mild to moderate psoriatic patients have been 
studied in an explorative manner by means of biomarkers using histologic, 
immunohistologic and topoproteomic techniques. The Global ANCOVA method, a 
linear model originally developed for the analysis of gene expression data, enabled the 
identification of a series of biomarkers suitable to characterize the disease in small 
groups of patients from a statistical point of view. Further, the distribution of the 
biomarkers in skin compartments was studied and association of these markers with 
clinical symptom scores was evaluated.  The selection of biomarkers, the strategy for 
data analysis and sample size calculations outlined in this study enable a detailed 
study planning in future for clinical trials with focus on biomarkers related to psoriasis.  
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12. Appendix 
 
Significance testing  in Global ANCOVA 
Based on the extra sum of squares principle, Global ANCOVA uses the multivariate 
test statistic 
 
(HI =  JKKLM − JKKNMJKKNM ∙ > − OP  
 
to prove the relevance of an independent variable.  RSSRM and RSSFM denote the 
residual sum of squares of the reduced and full model, respectively. These global sums 
of squares are calculated as a sum over the corresponding sums for each marker. The 
difference between the number of variables in the full and reduced model is f, q is the 
number of variables in the full model and n is the sample size. The null hypothesis of 
no group influence on the marker response can be tested using a classical F-test 
assuming an independent homoscedastic marker response. FGA is Fpf,p(n-q) distributed 
under this hypothesis where p is the number of markers. However, the assumption of 
homoscedastic marker response is not fulfilled in general. Therefore a permutation test 
has been implemented. The design matrix is split in two parts, containing covariates of 
interest and covariates for adjustment. Rows of the former matrix are permuted, 
whereas the latter is constant. For each permutation residual sums of squares are 
calculated for the full and reduced model. RSSRM is constant and does not depend on 
the permutations. Only RSSFM changes in this resampling procedure. For each 
permutation the test statistic shown in the formula above is calculated and the empirical 
p-value is the fraction of statistics exceeding FGA from the observed data. 
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 Bonferroni-Holm method for multiple testing 
The Bonferroni-Holm method is used to correct α-error accumulation in multiple 
comparisons. The calculation involves the following steps: 
 
▪ specify the global α-error αg. 
▪ calculate the individual p-values pi for n comparisons. 
▪ sort the p-values in an ascending manner 
▪ calculate individual α-errors αi for each test (i=1,.., n) 
 Q* =  ERST*U- 
▪ compare individual p-values pi with the corresponding αi reject all null hypothesis until  
 pi exceeds αi  
 
Alternatively, the individual p-values can be compared with the global α-error αg after 
multiplication by n-i+1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
